Bisphosphonate drug holidays in osteoporosis according to fracture risk profile
Authors' conclusion
We identified a profile of patients with osteoporosis who should not discontinue bisphosphonates, owing to the possibility of fractures, especially vertebral, which are already evident the first year after discontinuation.
Study context
- Population
- Postmenopausal women or men with osteoporosis who received alendronate or risedronate for ≥ 5 years or zoledronate for ≥ 3 years and discontinued treatment for ≥ 1 year or ≥ 2 years, respectively; 14 Spanish rheumatology departments
- Participants
- 264 women
- Exposure
- Fracture risk profile before bisphosphonate discontinuation: high vs moderate vs low risk
- Outcome
- Incidence of fractures and associated risk factors after bisphosphonate discontinuation
Methodological detailsobservational, multicentre (14 Spanish rheumatology departments)
- Observational
- Multicentre (14 Spanish rheumatology departments)
Main finding
As reported in the abstract
Fractures after bisphosphonate discontinuation
Patients with fractures (36 fractures, mainly clinical vertebral)
32
12.3%
Observational data: associations, not effects.
Further findings
Fracture by risk profile · 12 months
Bone mineral density (BMD)
- Significant BMD loss at femoral neck and total hip; duration of discontinuation the key factor
Bone turnover markers (BTMs)
- PINP the marker with the greatest changes
Original publication
Bisphosphonate drug holidays in osteoporosis according to fracture risk profile. Osteoporos Int. Published 3 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →